Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer.
暂无分享,去创建一个
T. Walsh | M. King | J. Stamatoyannopoulos | Ming K. Lee | S. Casadei | S. Stray | Jessica B. Mandell | B. Norquist
[1] Pascal Borry,et al. Statement of the ESHG on direct-to-consumer genetic testing for health-related purposes , 2010, European Journal of Human Genetics.
[2] Rochelle L. Garcia,et al. The molecular pathogenesis of hereditary ovarian carcinoma , 2010, Cancer.
[3] Bing Xia,et al. PALB2/FANCN: recombining cancer and Fanconi anemia. , 2010, Cancer research.
[4] A. Tutt,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.
[5] S. Narod. Testing for CHEK2 in the cancer genetics clinic: ready for prime time? , 2010, Clinical genetics.
[6] T. Walsh,et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing , 2010, Proceedings of the National Academy of Sciences.
[7] A. Hollestelle,et al. Discovering moderate-risk breast cancer susceptibility genes. , 2010, Current opinion in genetics & development.
[8] F. Sera,et al. A PALB2 germline mutation associated with hereditary breast cancer in Italy , 2010, Familial Cancer.
[9] A. Børresen-Dale,et al. Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study , 2010, Human mutation.
[10] M. Dąbrowska,et al. A novel germline PALB2 deletion in Polish breast and ovarian cancer patients , 2010, BMC Medical Genetics.
[11] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[12] Seema A Khan,et al. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[13] Alison P. Klein,et al. Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene , 2009, Science.
[14] Z. Shao,et al. The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives , 2009, Breast Cancer Research and Treatment.
[15] E. V. Rensburg,et al. PALB2 sequence variants in young South African breast cancer patients , 2009, Familial Cancer.
[16] M. Urioste,et al. Analysis of FANCB and FANCN/PALB2 Fanconi Anemia genes in BRCA1/2-negative Spanish breast cancer families , 2009, Breast Cancer Research and Treatment.
[17] Gail Javitt,et al. The current landscape for direct-to-consumer genetic testing: legal, ethical, and policy issues. , 2008, Annual review of genomics and human genetics.
[18] Alan Ashworth,et al. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Hopper,et al. Penetrance Analysis of the PALB2 c.1592delT Founder Mutation , 2008, Clinical Cancer Research.
[20] W. Foulkes,et al. Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women , 2007, Breast Cancer Research.
[21] Fergus J Couch,et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. , 2007, American journal of human genetics.
[22] Petra M. Nederlof,et al. Analysis of PALB2/FANCN-associated breast cancer families , 2007, Proceedings of the National Academy of Sciences.
[23] Katri Pylkäs,et al. A recurrent mutation in PALB2 in Finnish cancer families , 2007, Nature.
[24] Hans Joenje,et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2 , 2007, Nature Genetics.
[25] C. Mathew,et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer , 2007, Nature Genetics.
[26] S. Seal,et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.
[27] F. Couch,et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. , 2006, Molecular cell.
[28] T. Walsh,et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. , 2006, JAMA.
[29] B. Ward,et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] P. Das,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .
[31] J. Dungan. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .
[32] S. Narod. Testing for CHEK 2 in the cancer genetics clinic : ready for prime time ? , 2010 .
[33] M. Southey,et al. PenetranceAnalysis of the PALB 2 c . 1592 delT Founder Mutation , 2008 .